---
title: "AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS In DLBCL"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300992625.md"
description: "AbbVie and Genmab reported positive Phase 3 EPCORE DLBCL-2 trial results, showing epcoritamab plus R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma patients compared to R-CHOP alone. The combination was well-tolerated. Both companies plan to engage global regulatory authorities on next steps for the investigational treatment."
datetime: "2026-10-06T05:22:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300992625.md)
  - [en](https://longbridge.com/en/news/300992625.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300992625.md)
generator: "portal-rs"
---

# AbbVie, Genmab's Epcoritamab Plus R-CHOP Improves PFS In DLBCL

Add  as your preferred news source on Google

 Add Now

AbbVie (ABBV) and Genmab (GMAB) reported positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

The combination demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus R-CHOP alone in frontline diagnosed DLBCL patients. 

Epcoritamab is a subcutaneous T-cell-engaging bispecific antibody designed to bind CD3 on T cells and CD20 on B cells.

The global, randomized Phase 3 trial evaluated fixed-duration epcoritamab plus R-CHOP for six cycles followed by epcoritamab for two cycles, versus rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) followed by rituximab.

The combination was generally well tolerated, with a safety profile consistent with the individual treatments. 

Epcoritamab plus R-CHOP remains investigational. AbbVie and Genmab plan to engage global regulatory authorities on next steps.

ABBV closed on Monday at $265.76, up 1.12%. 

In the overnight market, shares are down 0.05% at $265.64. 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)

## Related News & Research

- [BUZZ-Genmab at 3-year high after blood cancer drug combination study results](https://longbridge.com/en/news/301001061.md)
- [Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug](https://longbridge.com/en/news/301009449.md)
- [HC Wainwright & Co. maintains Buy rating on Genmab, $50 price target](https://longbridge.com/en/news/301136681.md)
- [AbbVie says FDA grants breakthrough therapy status for ABBV-400 in metastatic colorectal cancer](https://longbridge.com/en/news/301144773.md)
- [Genmab holds extraordinary general meeting](https://longbridge.com/en/news/301166413.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**